Financial research concept

Oncology & Multispecialty Revenue

Oncology & Multispecialty revenue measures McKesson's sales from specialty distribution, provider solutions, research, technology, and practice-management activities.

By Lee BaileyPublished Sep 24, 2026
Research context

See what supports this page, how current it is, and where comparable or historical context is available.

Research date
Sep 24, 2026Use the dated article and cited sources for the definition, examples, and stated limitations.
Operating-model context
15 connected conceptsPart of the reviewed Healthcare Distribution & Services Economics; issuer definitions remain distinct where disclosed.
Company examples
1 reviewed companyRelationships reflect supported examples, not a normalized cross-company KPI ranking.
  1. What moves it
  2. Investor read-through
  3. Part of the Healthcare Distribution & Services Economics
  4. See It in Company Research
  5. Continue Research

oncology & multispecialty revenue is an issuer-specific segment revenue measure for McKesson's Oncology & Multispecialty business. McKesson reported fiscal 2026 Oncology & Multispecialty revenue of $48.423 billion, up 31% from $36.862 billion. Management attributed the increase primarily to provider-solution growth from added practices and higher specialty pharmaceutical sales.

What moves it

Revenue growth can reflect transaction volume, pharmaceutical or product mix, customer additions, acquisitions, pricing, and the mix between product distribution and services. For Oncology & Multispecialty, the underlying operating drivers should be read alongside the segment's profit and margin rather than treating revenue growth alone as value creation.

Investor read-through

McKesson's segment revenue is not a standardized industry KPI and does not imply equivalent economics across distributors or healthcare-service companies. Large pharmaceutical-distribution revenue bases can carry very different margins from technology or provider-service revenue, so compare the revenue measure with segment operating profit and segment operating margin.

Primary source: McKesson fiscal 2026 Form 10-K.

Part of the Healthcare Distribution & Services Economics

Connect pharmaceutical and medical distribution scale, specialty and prescription-technology profitability, service mix, and asset intensity to understand healthcare distribution and services economics.

How the model fits together
  • Core pharmaceutical distribution scale and margin: North American Pharmaceutical revenue shows the scale of McKesson's core distribution engine, while segment operating profit and margin show how a very large revenue base converts into segment earnings. Service revenue mix helps preserve the distinction between product-heavy distribution revenue and service-oriented economics.
  • Specialty care and prescription-technology economics: Oncology & Multispecialty and Prescription Technology Solutions pair revenue scale with segment profit and margin across specialty distribution, provider solutions, medication-access technology, and third-party logistics. Service revenue mix adds context for why these businesses can carry different economics without implying standardized peer margins.
  • Medical-surgical distribution and asset intensity: Medical-Surgical Solutions revenue, operating profit, and margin show the economics of non-acute distribution, while segment depreciation and amortization and long-lived-asset expenditures show different views of the asset base and current investment. Those capital measures are not interchangeable with each other or with total company capital expenditure.

See It in Company Research

These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.

Continue Research

Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.

Compare stocks

Compare healthcare distribution and services stocks

Continue into stock comparison after reviewing segment scale, profitability, service mix, and capital intensity across healthcare distribution and services businesses.

Continue research

Explore more topics in the Financial Research Encyclopedia.